drugset / Trial / NCT01151215

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215

Phase 2 Terminated 482 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone. The secondary objective is to investigate the safety and tolerability of AZD8931 given in combination with anastrozole.

Timeline

Start
2010-06
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject SAPITINIB Small molecule 20 mg Oral
Subject SAPITINIB Small molecule 40 mg Oral

Indications